Réactifs et instruments pour l'immunologie, la biologie cellulaire et la biologie moléculaire.

Paritaprevir [1216941-48-8]

Imprimer

Référence NB-64-11652-10mg

Conditionnement : 10mg

Marque : Neo Biotech

Demander plus d'informations

Remove All

Paritaprevir

(Synonyms: Veruprevir, ABT-450, ABT450, 1221573-85-8) Copy Product Info

Synonyms: Veruprevir, ABT-450, ABT450, 1221573-85-8

Catalog No. T22394 Copy Product Info

Purity: 99.72%

Paritaprevir free base (ABT-450) is an orally bioavailable, synthetic acylsulfonamide inhibitor of the hepatitis C virus (HCV) protease complex comprised of non-structural protein 3 and 4A (NS3/NS4A), with potential activity against HCV genotype 1. Upon administration, paritaprevir reversibly binds to the active center and binding site of the HCV NS3/NS4A protease and prevents NS3/NS4A protease-mediated polyprotein maturation. This disrupts both the processing of viral proteins and the formation of the viral replication complex, which inhibits viral replication in HCV genotype 1-infected host cells.

Cas No. 1216941-48-8

With extensive experience in compound synthesis, we can provide rapid custom synthesis services for this product according to your research needs.

For research use only—not for human use. No sales to individuals. Use as intended only.

Select Batch

Purity:99.72%

Appearance:Solid

Color:White

Product Introduction

Bioactivity

Description	Paritaprevir free base (ABT-450) is an orally bioavailable, synthetic acylsulfonamide inhibitor of the hepatitis C virus (HCV) protease complex comprised of non-structural protein 3 and 4A (NS3/NS4A), with potential activity against HCV genotype 1. Upon administration, paritaprevir reversibly binds to the active center and binding site of the HCV NS3/NS4A protease and prevents NS3/NS4A protease-mediated polyprotein maturation. This disrupts both the processing of viral proteins and the formation of the viral replication complex, which inhibits viral replication in HCV genotype 1-infected host cells.
Targets & IC50	HCV NS3/4A 1a:1.0 nM, HCV NS3/4A 6a:0.69nM, HCV NS3/4A 2a:5.3 nM, HCV 1a:1 nM(EC50), HCV 1b:0.21 nM(EC50), HCV NS3/4A 3a:19 nM, HCV NS3/4A 1b:0.21 nM, HCV NS3/4A 4a:0.09 nM
In vivo	Paritaprevir/ritonavir/ombitasvir with dasabuvir (PrOD) is a novel combination of a nonstructural (NS) 3/4A protein inhibitor boosted by ritonavir, an NS5A protein inhibitor, and an NS5B nonnucleoside polymerase inhibitor. The combination of paritaprevir, ritonavir, ombitasvir (an NS5A protein inhibitor), and dasabuvir (an NS5B non-nucleoside polymerase inhibitor) with or without RBV has been approved to treat HCV genotype 1 infections1[1].
Synonyms	Veruprevir, ABT-450, ABT450, 1221573-85-8

Chemical Properties

Molecular Weight	765.88
Formula	C₄₀H₄₃N₇O₇S
Cas No.	1216941-48-8
Smiles	Cc1cnc(cn1)C(=O)N[C@H]1CCCCC\C=C/[C@@H]2C[C@]2(NC(=O)[C@@H]2C[C@H](CN2C1=O)Oc1nc2ccccc2c2ccccc12)C(=O)NS(=O)(=O)C1CC1
Relative Density.	1.45 g/cm3 (Predicted)

Storage & Solubility Information

Storage

Keep away from direct sunlight,Keep away from moisture Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature.

Solubility Information

DMSO: 80 mg/mL (104.46 mM), Sonication is recommended.

In Vivo Formulation

10% DMSO+40% PEG300+5% Tween 80+45% Saline: 3.3 mg/mL (4.31 mM), Sonication is recommended.

Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.

Solution Preparation Table

DMSO

	1mg	5mg	10mg	50mg
1 mM	1.3057 mL	6.5284 mL	13.0569 mL	65.2844 mL
5 mM	0.2611 mL	1.3057 mL	2.6114 mL	13.0569 mL
10 mM	0.1306 mL	0.6528 mL	1.3057 mL	6.5284 mL
20 mM	0.0653 mL	0.3264 mL	0.6528 mL	3.2642 mL
50 mM	0.0261 mL	0.1306 mL	0.2611 mL	1.3057 mL
100 mM	0.0131 mL	0.0653 mL	0.1306 mL	0.6528 mL

Note : The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Calculator

Molarity Calculator
Dilution Calculator
Reconstitution Calculator
Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:

For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, and a total of 10 animals are to be administered, using a formulation of 10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH₂O , the resulting working solution concentration would be 2 mg/mL.

Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSO to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSO stock solution to 400 µL PEG300 and mix thoroughly until the solution becomes clear.

2) Add 50 µL Tween 80 and mix well until fully clarified.

3) Add 450 µL Saline,PBS or ddH₂O and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.

All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.

Dose Conversion

Keywords

T3226SARS-CoV 3CLPproSARS-CoVSARS coronavirusRitonavirParitaprevirorally activeNS3/4AInhibitorinhibitHepatitis C virusHCVProteaseHCV ProteaseHCV NS3/4AHCV genotype 1bHCV genotype 1aHCV 1bHCV 1aHCVCYP450ABT 450

Related Tags: Paritaprevir chemical structure | Paritaprevir in vivo | Paritaprevir formula | Paritaprevir molecular weight